Chemkart India Ltd
Incorporated in 2020, Chemkart India Limited, based in Mumbai, is a B2B nutraceutical ingredient distributor and processor.[1]
- Market Cap ₹ 161 Cr.
- Current Price ₹ 133
- High / Low ₹ 262 / 87.0
- Stock P/E 7.75
- Book Value ₹ 108
- Dividend Yield 0.00 %
- ROCE 28.5 %
- ROE 22.5 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company has a good return on equity (ROE) track record: 3 Years ROE 38.3%
- Promoter holding has increased by 1.35% over last quarter.
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Fast Moving Consumer Goods Fast Moving Consumer Goods Food Products Other Food Products
Part of BSE SME IPO
Half Yearly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| 87 | 131 | 132 | 203 | 213 | |
| 80 | 120 | 112 | 170 | 184 | |
| Operating Profit | 7 | 11 | 20 | 33 | 29 |
| OPM % | 8% | 9% | 15% | 16% | 14% |
| 0 | 0 | 1 | 2 | 1 | |
| Interest | 0 | 1 | 1 | 2 | 1 |
| Depreciation | 0 | 0 | 0 | 1 | 0 |
| Profit before tax | 7 | 11 | 19 | 33 | 28 |
| Tax % | 26% | 28% | 28% | 24% | 26% |
| 5 | 8 | 14 | 25 | 21 | |
| EPS in Rs | 40.46 | 58.73 | 102.73 | 26.06 | 17.17 |
| Dividend Payout % | -0% | -0% | -0% | -0% | -0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 17% |
| TTM: | 5% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 38% |
| TTM: | -16% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 42% |
| 3 Years: | 38% |
| Last Year: | 23% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Equity Capital | 1 | 1 | 1 | 10 | 12 |
| Reserves | 5 | 13 | 27 | 44 | 119 |
| 2 | 11 | 12 | 17 | 5 | |
| 17 | 15 | 13 | 16 | 22 | |
| Total Liabilities | 26 | 40 | 54 | 86 | 158 |
| 1 | 6 | 5 | 5 | 5 | |
| CWIP | -0 | -0 | -0 | -0 | -0 |
| Investments | -0 | -0 | -0 | 0 | 6 |
| 25 | 35 | 49 | 81 | 146 | |
| Total Assets | 26 | 40 | 54 | 86 | 158 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| -0 | 5 | -2 | -3 | -3 | |
| -1 | -5 | -0 | -0 | -0 | |
| 1 | 1 | 3 | 6 | 37 | |
| Net Cash Flow | -0 | 0 | -0 | 3 | 34 |
| Free Cash Flow | -1 | -1 | -3 | -4 | -4 |
| CFO/OP | 27% | 67% | 15% | 9% | 13% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Debtor Days | 81 | 62 | 88 | 83 | 86 |
| Inventory Days | 10 | 25 | 27 | 50 | 72 |
| Days Payable | 65 | 37 | 35 | 26 | 37 |
| Cash Conversion Cycle | 25 | 50 | 81 | 107 | 121 |
| Working Capital Days | 23 | 25 | 64 | 82 | 117 |
| ROCE % | 67% | 62% | 62% | 29% |
Insights
In beta| Mar 2024 | Sep 2025 | |
|---|---|---|
| Blending Capacity MT/Day |
|
|
| Domestic Revenue Share % |
||
| Employee Strength Number |
||
| Export Revenue Share % |
||
| Grinding Capacity MT/Day |
||
| Number of Ingredients Number |
||
| Number of Trusted Clients Number |
||
| Warehouse Space Sq. Ft. |
||
Extracted by Screener AI
Documents
Announcements
-
Regulation 32 For The Half Year Ended 31St March 2026.
18 May - Chemkart India reported no deviation in IPO proceeds usage for half year ended 31 March 2026.
-
Announcement under Regulation 30 (LODR)-Change in Management
18 May - Board approved audited FY26 standalone and consolidated results; appointed internal and secretarial auditors on 18 May 2026.
-
Announcement under Regulation 30 (LODR)-Change in Management
18 May - Board approved FY26 audited standalone/consolidated results; unmodified opinion; appointed internal and secretarial auditors.
-
Announcement under Regulation 30 (LODR)-Investor Presentation
18 May - Investor''s Presentation based on Financial Results for the Half Year and the Financial Year ended 31st March 2026.
-
Board Meeting Outcome for 18Th May 2026.
18 May - Board approved FY26 audited standalone and consolidated results; appointed internal and secretarial auditors.
Annual reports
No data available.
Business Segment[1]
a) Trading Business:(97% of H1FY25 revenue)[2]
The company sources a wide range of nutraceutical ingredients—such as amino acids, vitamins, herbal extracts, and proteins—mainly through imports, and supplies them to B2B clients for manufacturing finished supplements.